[Wnt/β-catenin signal pathway mediated Salidroside induced directional differentiation from mouse mesenchymal stem cells to nerve cells].
Guo C, Liu R, Zhao HB, Qin GH
Salidroside helps mouse stem cells turn into nerve cells by activating the Wnt/β-catenin and calcium signaling pathways, which are important for brain cell development.
- Salidroside promotes stem cells to become nerve cells
- Wnt/β-catenin pathway is key to this process
- Calcium signaling also supports the change
- Nurr1, a gene linked to NR4A2, increases with Salidroside
- This suggests possible pathways for future therapies
Orphan nuclear receptor NR4A2 induces transcription of the immunomodulatory peptide hormone prolactin.
McCoy JM, Walkenhorst DE, McCauley KS, Elaasar H, Everett JR, Mix KS
NR4A2 directly turns on the prolactin gene in joint cells, leading to a large increase in prolactin protein, which promotes inflammation and tissue damage in arthritis. This discovery reveals a new pathway that may drive joint disease and could point to treatments targeting NR4A2 or prolactin.
- NR4A2 strongly activates the prolactin gene in joint cells
- Prolactin levels rise 300-fold in response to NR4A2
- Prolactin drives inflammation and cell growth in joints
- Blocking NR4A2 reduces prolactin production by 95%
- This pathway may worsen arthritis and be a treatment target
Epigenetic basis of opiate suppression of Bdnf gene expression in the ventral tegmental area.
Koo JW, Mazei-Robison MS, LaPlant Q, Egervari G, Braunscheidel KM, Adank DN, Ferguson D, Feng J, Sun H, Scobie KN, Damez-Werno DM, Ribeiro E, Peña CJ, Walker D, Bagot RC, Cahill ME, Anderson SA, Labonté B, Hodes GE, Browne H, Chadwick B, Robison AJ, Vialou VF, Dias C, Lorsch Z, Mouzon E, Lobo MK, Dietz DM, Russo SJ, Neve RL, Hurd YL, Nestler EJ
Chronic opiate use reduces BDNF gene activity in a key brain region through lasting epigenetic changes, including altered histone marks and reduced NURR1 levels, which together impair brain plasticity and contribute to addiction-related behaviors.
- Opiates persistently reduce BDNF in the VTA via epigenetic changes
- NURR1 levels drop, worsening BDNF suppression
- Altered histone marks and RNA polymerase stalling block gene expression
- These changes link to long-term behavioral adaptations to opioids
- Epigenetic mechanisms may be targets for future treatments
T-Brain-1--A Potential Master Regulator in Autism Spectrum Disorders.
Chuang HC, Huang TN, Hsueh YP
TBR1, a gene linked to autism, controls a network of other autism-related genes, including NR4A2, which is involved in brain development and function. This network includes genes that regulate neuron connections, migration, and activity, suggesting TBR1 acts as a master switch in autism-related brain changes.
- TBR1 regulates 24 autism-linked genes, including NR4A2
- NR4A2 is part of a cascade affecting brain development
- Altered expression of key genes disrupts neuron connections and activity
- Findings point to potential pathways for future autism treatments
- TBR1 dysfunction may disrupt brain wiring through multiple gene targets
Hormonal modulation of catecholaminergic neurotransmission in a prenatal stress model.
Pallarés ME, Antonelli MC
Prenatal stress in mice alters dopamine and norepinephrine systems in offspring, with lasting changes in brain chemistry and behavior that depend on hormonal shifts during puberty. These changes involve key genes like NR4A2 (Nurr1), which is sensitive to early-life stress and may disrupt brain development similarly to NR4A2-related syndrome. The findings suggest that hormonal imbalances from early stress can interfere with brain wiring, especially during critical developmental windows.
- Prenatal stress alters dopamine and norepinephrine systems in offspring
- NR4A2 (Nurr1) is highly sensitive to prenatal stress
- Changes depend on puberty-related hormone surges
- Early stress may disrupt brain development like NR4A2 syndrome
- Findings highlight timing of brain development vulnerability
A case of severe hyperaldosteronism caused by a de novo mutation affecting a critical salt bridge Kir3.4 residue.
Monticone S, Bandulik S, Stindl J, Zilbermint M, Dedov I, Mulatero P, Allgaeuer M, Lee CC, Stratakis CA, Williams TA, Tiulpakov A
A rare genetic mutation in the KCNJ5 gene causes severe primary aldosteronism in a young child, leading to life-threatening high blood pressure, low potassium, and symptoms resembling diabetes insipidus. The mutation disrupts a key ion channel, triggering abnormal adrenal hormone production, including NR4A2, which drives the disease. The condition is not responsive to standard treatments like tertiapin-Q or verapamil.
- A new KCNJ5 mutation causes severe aldosteronism in infancy
- Mutant channel leads to high NR4A2 and aldosterone levels
- Child shows diabetes insipidus-like symptoms and low potassium
- Standard treatments do not work on this mutation
- NR4A2 is directly involved in hormone overproduction
Regulation of dopaminergic markers expression in response to acute and chronic morphine and to morphine withdrawal.
García-Pérez D, Núñez C, Laorden ML, Milanés MV
Chronic morphine use and withdrawal alter key dopamine-related genes and proteins in brain regions linked to reward and addiction, with changes tied to the activity of two critical transcription factors, Nurr1 and Pitx3, which help maintain dopamine neurons.
- Morphine dependence and withdrawal change dopamine markers in reward brain areas
- Nurr1 and Pitx3 levels rise during morphine dependence and withdrawal
- These transcription factors regulate dopamine genes linked to addiction
- Changes in dopamine signaling may underlie addiction-related brain adaptations
- Findings highlight Nurr1 and Pitx3 as potential targets for treatment
The NR4A nuclear receptors as potential targets for anti-aging interventions.
Paillasse MR, de Medina P
NR4A nuclear receptors, including NR4A2, help regulate mitochondria, repair DNA, and protect cells from stress—key processes in aging. Targeting these receptors may slow aging and reduce the risk of age-related diseases like neurodegeneration and diabetes.
- NR4A2 helps maintain healthy mitochondria
- NR4A2 supports DNA repair and cellular protection
- NR4A receptors are activated by stress and promote resilience
- Targeting NR4A2 may delay aging and disease
- NR4A2 is linked to neurodegenerative and metabolic conditions
NURR1 involvement in recombinant tissue-type plasminogen activator treatment complications after ischemic stroke.
Merino-Zamorano C, Hernández-Guillamon M, Jullienne A, Le Béhot A, Bardou I, Parés M, Fernández-Cadenas I, Giralt D, Carrera C, Ribó M, Vivien D, Ali C, Rosell A, Montaner J
NURR1 levels rise in response to stroke treatment with r-tPA, and high levels are linked to increased risk of bleeding complications. Blocking NURR1 reduces harmful inflammation and protects blood vessels in the brain. Patients who had bleeding after treatment had higher NURR1 levels before treatment.
- NURR1 increases during r-tPA stroke treatment
- High NURR1 levels predict bleeding risk
- Blocking NURR1 reduces brain vessel damage
- NURR1 may be a target to prevent bleeding
- Higher baseline NURR1 linked to worse outcomes
Nurr1 blocks the mitogenic effect of FGF-2 and EGF, inducing olfactory bulb neural stem cells to adopt dopaminergic and dopaminergic-GABAergic neuronal phenotypes.
Vergaño-Vera E, Díaz-Guerra E, Rodríguez-Traver E, Méndez-Gómez HR, Solís Ó, Pignatelli J, Pickel J, Lee SH, Moratalla R, Vicario-Abejón C
Overexpressing the Nurr1 protein in olfactory bulb stem cells stops them from dividing and turns them into mature dopamine-producing neurons, including a special type that also makes GABA. These cells can release dopamine, respond to dopamine signals, and show features of brain cells found in the midbrain and olfactory bulb.
- Nurr1 stops stem cells from dividing
- Turns stem cells into dopamine-making neurons
- Creates neurons that also make GABA
- Cells release dopamine and respond to dopamine signals
- Nurr1 may work by increasing Fgfr2 levels
Neural stem cells in Parkinson's disease: a role for neurogenesis defects in onset and progression.
Le Grand JN, Gonzalez-Cano L, Pavlou MA, Schwamborn JC
Parkinson's disease may begin as a developmental issue due to problems in creating new brain cells, especially dopamine-producing neurons, even before symptoms appear. Genes linked to Parkinson's, including NR4A2 (Nurr1), also play key roles in brain cell development and maintenance.
- Parkinson's may start with faulty brain cell development
- NR4A2/Nurr1 is involved in making dopamine neurons
- Defects in neurogenesis may explain early non-motor symptoms
- PD genes affect stem cells and neuron formation
- This suggests Parkinson's is both a degenerative and developmental disorder
Novel para-phenyl substituted diindolylmethanes protect against MPTP neurotoxicity and suppress glial activation in a mouse model of Parkinson's disease.
De Miranda BR, Popichak KA, Hammond SL, Miller JA, Safe S, Tjalkens RB
C-DIM12, a compound that activates the NR4A2/Nurr1 protein, protects dopamine-producing brain cells in a mouse model of Parkinson's disease by reducing brain inflammation and supporting the health of these neurons. It works by blocking harmful glial cell activation and preserving Nurr1 function, which helps maintain dopamine production.
- C-DIM12 protects dopamine neurons in Parkinson's mouse models
- It reduces brain inflammation by blocking glial activation
- It boosts Nurr1 activity, helping neurons make dopamine
- Treatment started after damage still provided protection
- C-DIM12 is the most effective among tested compounds
Comparative pathway and network analysis of brain transcriptome changes during adult aging and in Parkinson's disease.
Glaab E, Schneider R
NR4A2, a gene linked to Parkinson's disease, is significantly under-expressed in both aging brains and Parkinson's disease, suggesting that age-related declines in NR4A2 may increase Parkinson's risk. This shared pattern points to common biological pathways that could be targeted for early detection or treatment.
- NR4A2 is under-expressed in aging and Parkinson's disease
- Age-related NR4A2 decline may raise Parkinson's risk
- Shared gene changes suggest common disease mechanisms
- Metallothioneins are over-expressed, indicating oxidative stress
- NR4A2 findings may help develop early biomarkers
Differences in prefrontal cortex GABA/glutamate ratio after acute restraint stress in rats are associated with specific behavioral and neurobiological patterns.
Drouet JB, Fauvelle F, Maunoir-Regimbal S, Fidier N, Maury R, Peinnequin A, Denis J, Buguet A, Canini F
Rats with a higher GABA/glutamate ratio in the prefrontal cortex after stress showed reduced brain activity, stronger stress hormone responses, and more severe behavioral changes, suggesting this chemical balance influences how individuals react to stress.
- High GABA/glutamate ratio linked to weaker brain activation under stress
- Higher stress hormone and liver enzyme levels in high-ratio rats
- Reduced movement and behavioral changes seen in high-ratio group
- No difference in energy metabolism between groups
- GABA/glutamate balance may shape individual stress responses
[Experimental animal model of multiple sclerosis--transverse investigation of MS pathogenesis for therapeutic intervention].
Oki S, Yamamura T
NR4A2 is highly active in immune cells that drive multiple sclerosis, and blocking it reduces disease severity in animal models, suggesting it could be a promising target for new treatments.
- NR4A2 is overactive in MS immune cells
- It is found in harmful IL-17-producing T cells
- Blocking NR4A2 improves symptoms in MS animal models
- NR4A2 may be a new treatment target for MS
Shikonin, a constituent of Lithospermum erythrorhizon exhibits anti-allergic effects by suppressing orphan nuclear receptor Nr4a family gene expression as a new prototype of calcineurin inhibitors in mast cells.
Wang X, Hayashi S, Umezaki M, Yamamoto T, Kageyama-Yahara N, Kondo T, Kadowaki M
Shikonin, a compound from a traditional herb, reduces allergic reactions by blocking mast cell activation through a newly identified pathway involving the NR4A2 gene and calcineurin. It works similarly to known immunosuppressants but may offer a safer or more targeted approach for treating allergic diseases.
- Shikonin blocks mast cell activation linked to allergies
- It reduces NR4A2 and other NR4A genes involved in inflammation
- It acts by inhibiting calcineurin, a key immune pathway
- This suggests potential for treating allergic conditions like food allergy
- Found effective in mouse mast cells, not yet tested in humans
miR-206 modulates lipopolysaccharide-mediated inflammatory cytokine production in human astrocytes.
Duan X, Zohaib A, Li Y, Zhu B, Ye J, Wan S, Xu Q, Song Y, Chen H, Cao S
miR-206 increases inflammation in human brain cells by suppressing NR4A2, a gene linked to NR4A2-related syndrome. Lower NR4A2 levels lead to greater inflammatory responses, which may worsen neurological symptoms in affected children.
- miR-206 boosts brain cell inflammation by blocking NR4A2
- NR4A2 loss worsens inflammatory responses in brain cells
- Inflammation pathways involving NF-kB and AP-1 are affected
- This mechanism may worsen neurological symptoms in NR4A2 syndrome
- Targeting miR-206 could be a potential therapy approach
ReNCell VM conditioned medium enhances the induction of dental pulp stem cells into dopaminergic like cells.
Gnanasegaran N, Govindasamy V, Musa S, Abu Kasim NH
Pre-treating dental pulp stem cells with conditioned medium from neuron-like cells boosts their ability to become dopamine-producing cells, which may improve future cell therapies for neurological conditions like NR4A2-related syndrome.
- Pre-conditioning SHED cells enhances their development into dopamine-like cells
- Key dopaminergic markers, including NR4A2, increased significantly
- This method may improve stem cell therapy outcomes for brain disorders
- The approach mimics natural neuron environments to boost cell readiness
- Findings suggest priming stem cells before transplant could be beneficial
A high-efficiency induction of dopaminergic cells from human umbilical mesenchymal stem cells for the treatment of hemiparkinsonian rats.
Ko TL, Fu YY, Shih YH, Lin YH, Ko MH, Fu TW, Lin TY, Hsiao HS, Chu PM, Fu YS
Boosting Nurr1 expression in human umbilical stem cells dramatically increases their ability to become dopamine-producing cells, which can improve movement symptoms in a rat model of Parkinson's disease. These engineered cells survive and function for at least three months after transplantation.
- Nurr1 boost increases dopamine cell yield from 12.7% to 71%
- Engineered cells make and release dopamine effectively
- Transplanted cells improve movement in Parkinson's rats
- Cells survive in the brain for at least 3 months
- Combining Nurr1 with key growth factors enhances differentiation
3,4-dihydroxyphenylethanol attenuates spatio-cognitive deficits in an Alzheimer's disease mouse model: modulation of the molecular signals in neuronal survival-apoptotic programs.
Arunsundar M, Shanmugarajan TS, Ravichandran V
DOPET, a compound found in olive oil and related to dopamine, improved memory and learning in mice with Alzheimer's-like brain damage by protecting brain cells from death and supporting key survival pathways. It reversed harmful changes in brain signaling and preserved mitochondrial health.
- DOPET improved memory and learning in Alzheimer's-like mice
- It protected brain cells by balancing survival and death signals
- DOPET preserved mitochondrial structure and function
- It boosted levels of brain-protective genes like Nurr1 and BDNF
- Results suggest DOPET may help protect neurons in neurodegenerative diseases
Midbrain cues dictate differentiation of human dental pulp stem cells towards functional dopaminergic neurons.
Kanafi M, Majumdar D, Bhonde R, Gupta P, Datta I
Human dental pulp stem cells can be guided by midbrain signals to become functional dopamine-producing neurons, which may offer a new source for treating Parkinson's disease and related conditions involving dopamine loss.
- Dental pulp stem cells can turn into dopamine-making neurons
- Midbrain signals boost key dopamine genes and proteins
- These engineered cells release dopamine when stimulated
- Cells show neuron-like electrical activity and calcium responses
- Potential for regenerative therapies in dopamine-related disorders
Effects of isoxazolo-pyridinone 7e, a potent activator of the Nurr1 signaling pathway, on experimental autoimmune encephalomyelitis in mice.
Montarolo F, Raffaele C, Perga S, Martire S, Finardi A, Furlan R, Hintermann S, Bertolotto A
Activating the Nurr1 protein with a drug called isoxazolo-pyridinone 7e reduces inflammation and nerve damage in a mouse model of multiple sclerosis, a disease that shares some features with NR4A2-related syndrome. The drug works by blocking a key inflammatory pathway, suggesting a potential treatment strategy.
- Nurr1 activation reduces MS-like symptoms in mice
- Drug blocks NF-kB, a major inflammation driver
- May protect nerves from damage in neuroinflammatory diseases
- Supports Nurr1 as a therapeutic target for brain disorders
Activation of TGFβ1 signaling enhances early dopaminergic differentiation in unrestricted somatic stem cells.
Khanghahi AM, Zeynali B, Akhlaghpoor A, Tafreshi AP, Krieglstein K
Activating the TGFβ1 signaling pathway boosts the early development of dopamine-producing neurons from unrestricted somatic stem cells, suggesting a potential way to improve stem cell-based therapies for conditions involving dopamine neuron loss.
- TGFβ1 enhances early dopamine neuron formation in stem cells
- TGFβ1 increases key markers for neurons and dopamine cells
- Blocking TGFβ reduces neuron development
- This pathway may help guide stem cells toward dopamine-producing fates
Correlation between orphan nuclear receptor Nurr1 expression and amyloid deposition in 5XFAD mice, an animal model of Alzheimer's disease.
Moon M, Jeong I, Kim CH, Kim J, Lee PK, Mook-Jung I, Leblanc P, Kim KS
Nurr1, a protein linked to brain health, is found in brain areas where amyloid-beta builds up in a mouse model of Alzheimer's disease. Its levels drop as the disease progresses, suggesting Nurr1 may play a role in protecting against Alzheimer's-like damage.
- Nurr1 is present in brain regions with amyloid-beta buildup
- Nurr1 levels decrease as Alzheimer's-like plaques increase
- Nurr1 may help protect brain cells from Alzheimer's damage
- Changes in Nurr1 happen early in disease progression
C19MC microRNAs regulate the migration of human trophoblasts.
Xie L, Mouillet JF, Chu T, Parks WT, Sadovsky E, Knöfler M, Sadovsky Y
C19MC microRNAs reduce the movement of placental cells that invade the uterus during early pregnancy, with one specific microRNA, miR-519d, targeting NR4A2 and other genes to control this process.
- C19MC microRNAs limit trophoblast migration in the placenta
- miR-519d targets NR4A2 to affect cell movement
- NR4A2 is directly regulated by a placental microRNA
- This regulation may influence early pregnancy development
- No effect on cell growth or death was observed
The NR4A receptors Nurr1 and Nur77 are increased in human placenta from women with gestational diabetes.
Lappas M
Nurr1 and Nur77 levels are higher in the placenta of women with gestational diabetes, and these proteins help control inflammation. Lowering Nurr1 or Nur77 reduces the production of inflammatory signals, suggesting they influence placental function and nutrient transport.
- Nurr1 and Nur77 are elevated in placenta from women with gestational diabetes
- These proteins increase inflammation in placental cells
- Reducing Nurr1 or Nur77 lowers harmful inflammatory signals
- This may affect how nutrients move across the placenta
- Suggests a potential role in placental health during pregnancy
Longitudinal Analysis of DNA Methylation in CD34+ Hematopoietic Progenitors in Myelodysplastic Syndrome.
Wong YF, Micklem CN, Taguchi M, Itonaga H, Sawayama Y, Imanishi D, Nishikawa S, Miyazaki Y, Jakt LM
NR4A2 is suppressed by DNA methylation in blood stem cells of MDS patients, and its reduced activity may contribute to abnormal stem cell growth. This suggests that NR4A2 could play a role in MDS progression and might be a target for future treatments.
- NR4A2 is silenced by DNA methylation in MDS stem cells
- Low NR4A2 levels may drive excessive stem cell growth
- MDS stem cells resist full demethylation by AZA treatment
- NR4A2 suppression may contribute to disease progression
Angiotensin II triggers expression of the adrenal gland zona glomerulosa-specific 3β-hydroxysteroid dehydrogenase isoenzyme through de novo protein synthesis of the orphan nuclear receptors NGFIB and NURR1.
Ota T, Doi M, Yamazaki F, Yarimizu D, Okada K, Murai I, Hayashi H, Kunisue S, Nakagawa Y, Okamura H
Angiotensin II triggers the production of a specific enzyme, HSD3B1, in adrenal cells that make aldosterone by activating two nuclear receptors, NGFIB and NURR1, which are required for this enzyme's expression. This pathway explains how the adrenal gland rapidly ramps up aldosterone-making capacity when needed.
- Angiotensin II boosts HSD3B1 enzyme in adrenal zona glomerulosa
- NGFIB and NURR1 are essential for this response
- HSD3B1 is the key enzyme for aldosterone production
- This pathway controls rapid aldosterone synthesis
- NURR1 is the same protein as NR4A2
The NR4A orphan nuclear receptors: mediators in metabolism and diseases.
Ranhotra HS
NR4A2 (Nurr1) is a key gene regulator involved in brain development, metabolism, and immune function, with strong links to neurological and metabolic diseases. Mutations in NR4A2 cause a rare neurodevelopmental syndrome with features like intellectual disability and movement disorders.
- NR4A2 regulates brain development and function
- NR4A2 mutations cause a known neurodevelopmental syndrome
- NR4A2 influences metabolism and immune responses
- NR4A2 is linked to Parkinson’s and other neurological conditions
- NR4A2 activity may be targeted for future therapies
Wnt/β-catenin signaling is required to rescue midbrain dopaminergic progenitors and promote neurorepair in ageing mouse model of Parkinson's disease.
L'Episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC, Serapide MF, Pluchino S, Marchetti B
Activating Wnt/β-catenin signaling helps restore dopamine-producing neurons in aged mice with Parkinson’s-like brain damage, improving movement symptoms. This suggests a potential treatment strategy to repair brain function in Parkinson’s disease.
- Wnt signaling declines with age, reducing brain repair ability
- Boosting Wnt/β-catenin activity restores dopamine neuron formation
- A drug targeting GSK-3β activated this repair pathway
- Improved movement symptoms were seen in treated mice
- Findings may lead to new Parkinson’s treatments
The Shh coreceptor Cdo is required for differentiation of midbrain dopaminergic neurons.
Kwon YR, Jeong MH, Leem YE, Lee SJ, Kim HJ, Bae GU, Kang JS
Cdo helps activate Sonic hedgehog (Shh) signaling, which is essential for making midbrain dopamine neurons. Without Cdo, the development of these neurons is impaired, and their formation can be restored by boosting Shh signaling with a drug.
- Cdo enhances Shh signaling needed for dopamine neuron development
- Cdo loss reduces dopamine neuron formation and increases cell death
- Key genes for dopamine neurons are underactive without Cdo
- A drug that activates Shh can fix the defect in Cdo-deficient cells
- Cdo is critical for efficient dopamine neuron production
Cell-based assays for Parkinson's disease using differentiated human LUHMES cells.
Zhang XM, Yin M, Zhang MH
Differentiated LUHMES cells model human dopaminergic neurons and can be used to test drugs that protect against Parkinson's disease-related damage from toxins or alpha-synuclein buildup.
- LUHMES cells become dopamine-producing neurons after differentiation
- Toxins and alpha-synuclein reduce cell energy and trigger cell death
- Two drugs reversed cell damage in this model
- This system helps find potential Parkinson's treatments
MC1R and NR4A receptors in cellular stress and DNA repair: implications for UVR protection.
Yin K, Sturm RA, Smith AG
NR4A2 is activated in response to UV damage in skin cells and helps protect DNA and reduce cancer risk, making it a promising target for new skin cancer treatments. Synthetic drugs that boost NR4A2 activity may offer a way to strengthen the skin's natural defenses.
- NR4A2 helps protect skin cells from UV damage
- It supports DNA repair and reduces cancer risk
- New drugs targeting NR4A2 may prevent skin cancer
- NR4A2 is activated by UV stress in melanocytes
Diverse roles for Wnt7a in ventral midbrain neurogenesis and dopaminergic axon morphogenesis.
Fernando CV, Kele J, Bye CR, Niclis JC, Alsanie W, Blakely BD, Stenman J, Turner BJ, Parish CL
Wnt7a is a key protein that guides the development of dopamine-producing brain cells in the midbrain, controlling how many cells are made, how they grow, and how their connections form. It acts at different times and places to promote neuron survival, regulate cell division, and direct axon paths to the right brain regions.
- Wnt7a controls the number of dopamine neurons made in the midbrain
- It guides axons to grow correctly and avoid wrong paths
- Wnt7a works through a known signaling pathway (β-catenin)
- Disruption may affect brain wiring linked to movement and behavior
- Findings may inform future therapies for NR4A2-related disorders
NR4A nuclear receptors are orphans but not lonesome.
Kurakula K, Koenis DS, van Tiel CM, de Vries CJ
NR4A nuclear receptors, including Nurr1 (NR4A2), play critical roles in brain function, immunity, and metabolism, but no natural activators have been found for them. Their activity is controlled by protein interactions, modifications, and transcriptional regulation rather than by traditional hormone-like ligands.
- NR4A2 (Nurr1) is vital for brain development and function
- No natural activators (ligands) have been identified for NR4A receptors
- Their activity is mainly regulated by protein interactions and modifications
- Nurr1's interactome is complex and still being mapped
- Understanding these interactions may lead to new treatment strategies